Stock Scorecard
Stock Summary for TRACON Pharmaceuticals Inc (TCON) - $0.43 as of 3/29/2024 8:10:52 AM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TCON
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TCON
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TCON
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for TCON
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for TCON
Financial Details for TCON
Company Overview |
|
---|---|
Ticker | TCON |
Company Name | TRACON Pharmaceuticals Inc |
Country | USA |
Description | TRACON Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for cancer and age-related macular degeneration and fibrotic diseases in the United States. The company is headquartered in San Diego, California. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/8/2024 |
Stock Price History |
|
Last Day Price | 0.43 |
Last Day Price Updated | 3/29/2024 8:10:52 AM EST |
Last Day Volume | 3,133,932 |
Average Daily Volume | 5,069,800 |
52-Week High | 2.14 |
52-Week Low | 0.13 |
Last Price to 52 Week Low | 230.77% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 67.80 |
Sector PE | 62.25 |
5-Year Average PE | -1.46 |
Free Cash Flow Ratio | 2.26 |
Industry Free Cash Flow Ratio | 17.19 |
Sector Free Cash Flow Ratio | 31.21 |
Current Ratio Most Recent Quarter | 0.89 |
Total Cash Per Share | 0.19 |
Book Value Per Share Most Recent Quarter | -0.02 |
Price to Book Ratio | 11.83 |
Industry Price to Book Ratio | 7.28 |
Sector Price to Book Ratio | 21.72 |
Price to Sales Ratio Twelve Trailing Months | 1.68 |
Industry Price to Sales Ratio Twelve Trailing Months | 32.57 |
Sector Price to Sales Ratio Twelve Trailing Months | 8.86 |
Share Statistics |
|
Total Shares Outstanding | 45,504,500 |
Market Capitalization | 19,566,935 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 87.68% |
Reported EPS 12 Trailing Months | -0.11 |
Reported EPS Past Year | 0.16 |
Reported EPS Prior Year | -1.40 |
Net Income Twelve Trailing Months | -3,588,000 |
Net Income Past Year | -3,588,000 |
Net Income Prior Year | -29,135,000 |
Quarterly Revenue Growth YOY | 0.00% |
5-Year Revenue Growth | 32.05% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 8,600,000 |
Total Cash Past Year | 8,600,000 |
Total Cash Prior Year | 17,500,000 |
Net Cash Position Most Recent Quarter | 8,600,000 |
Net Cash Position Past Year | -1,207,000 |
Long Term Debt Past Year | 9,807,000 |
Long Term Debt Prior Year | 9,807,000 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | -0.09 |
Equity to Debt Ratio Most Recent Quarter | 0.00 |
Total Stockholder Equity Past Year | -809,000 |
Total Stockholder Equity Prior Year | -7,151,000 |
Total Stockholder Equity Most Recent Quarter | -809,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.06 |
MACD Signal | 0.06 |
20-Day Bollinger Lower Band | 0.05 |
20-Day Bollinger Middle Band | 0.22 |
20-Day Bollinger Upper Band | 0.40 |
Beta | 0.79 |
RSI | 57.61 |
50-Day SMA | 0.36 |
200-Day SMA | 3.00 |
System |
|
Modified | 3/29/2024 8:10:55 AM EST |